Sign up
Pharma Capital
Why invest in DXB?

Dimerix: Access latest PPT from Proactive's CEO Sessions

Kathy Harrison talked pending milestone news with investors.
Dimerix: Access latest PPT from Proactive's CEO Sessions
Kathy Harrison, CEO, Dimerix

Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

The company will have milestone news flow in coming months from its Phase II clinical trials for chronic kidney disease.

The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).

The innovative treatment combines two existing drugs.


Register here to be notified of future DXB Company articles
View full DXB profile

Dimerix Ltd Timeline

View All

Related Articles

If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.